Sequencing determines SPR mutation in twins.
 

The REMBRANDT data portal provides researchers with access to data characterizing human brain neoplasias, including astrocytoma, GBM, oligodendroglioma, and other less-well-defined types (mixed, unknown, unclassified) as well as normal controls. The portal contains subject-annotation data focusing on survival for 668 subjects and two sets of microarray-based data sets, the first with copy-number data mapped to 241 subjects and the second with gene-expression data mapped to 579 subjects. A joint initiative of NCI and the National Institute of Neurological Disorders and Stroke (NINDS), REMBRANDT is a project of the NCI Division of Cancer Treatment and Diagnosis (DCTD) Cancer Diagnosis Program.

Go to "public studies" menu at the top right, and select "REMBRANDT" from the drop down options

Developed by NCI CBIIT in collaboration with the Nature Publishing Group (NPG), the PID provides researchers with information about known biomolecular interactions and cellular processes assembled into signaling pathways. It contains data describing 137 human pathways curated by NCI and NPG as well as 322 human pathways imported from Biocarta/Reactome. Pathway categories are provided courtesy of the Rat Genome Database  Pathway Ontology.

The NCI CBIIT instance of NBIA is an image repository that provides researchers with access to medical imaging libraries (also known as "collections") obtained from patients evaluated for multiple types of cancer (or, in one case, osteoarthritis). Images are stored in the Digital Imaging and Communications in Medicine (DICOM) standard and accompanied by image mark ups, annotations, and metadata. A wide range of imaging modalities is represented in the collections: computed radiography (CR), computed tomography (CT), digital radiography (DX), hard copy (HC), histopathology, magnetic resonance (MR), nuclear medicine (NM), ophthalmic photography (OP), presentation state (PR), positron emission tomography (PT), radiographic imaging (conventional film/screen) (RG), radiotherapy dose (RTDOSE), radiotherapy plan (RTPLAN), radiotherapy treatment record (RTRECORD), radiotherapy structure set (RTSTRUCT), secondary capture (SC), SR document, ultrasound (US), and X-ray angiography (XA).

The NCI CBIIT instance of caNanoLab is a nanoparticle annotation and data-sharing portal that provides researchers with data relating to the characterization of nanoparticle samples, protocols involving nanoparticles, and associated publications. It was developed for the NCI Nano Alliance, part of the NCI Center for Strategic Scientific Initiatives. The portal contains data describing a total of 989 samples of 17 distinct nanomaterial entities: biopolymers, carbon black particles, carbon nanotubes, carbon particles, dendrimers, emulsions, fullerenes, liposomes, metal oxides, metal particles, metalloids, nanohorns, nanorods, nanoshells, polymers, quantum dots, and silica particles. Sample characterizations include these information elements:

The NCI CBIIT instance of caMOD is a publicly accessible database that provides researchers with detailed information about animal models of human cancers. It was developed in collaboration with the Mouse Models of Human Cancer Consortium (MMHCC) in the Division of Cancer Biology. The database contains 6,084 records. Species represented are Mus musculus, Rattus norvegicus, Rattus rattus, Danio rerio, Felis catus, Canis familiarus, Capra hircus, Mesocricetus auratus, Equus caballus, Oryctolagus cuniculus, and Ovis aries. Information elements include organism, strain, genetic profile, histopathology, derived cell lines, images, carcinogenic agents, and therapeutic trials in which the models were used.

With the NCI CBIIT instance of CGWB, researchers can visualize and analyze in an integrated manner, somatic-mutation, gene-expression, copy-number variation, next-generation sequencing, and methylation data generated by multi-platform genome-wide assays. CGWB provides access to data drawn from a number of projects including The Cancer Genome Atlas (TCGA), the Therapeutically Applicable Research to Generate Effective Treatments (TARGET), the Tumor Sequencing Project (TSP) , and the Catalogue of Somatic Mutations in Cancer (COSMIC) , as well as data relating to the NCI60 cell lines. The application offers investigators three main analytical views: an integrated view using the University of California at Santa Cruz Genome Browser; a heat-map view that associates gene-e

CGAP, an initiative of the NCI Office of Cancer Genomics, offers researchers access to publicly accessible databases containing a wide variety of data types. Researchers can download much of the CGAP data in a tab-separated ASCII format via ftp.

The caIntegrator Data Portal provides researchers with centralized access to public genomic, clinical, and imaging data drawn from the following studies, each of which focuses on specific disease types

caArray is an open-source, web and programmatically accessible microarray data management system that supports the annotation of microarray data using MAGE-TAB and web-based forms. Data and annotations may be kept private to the owner, shared with user-defined collaboration groups, or made public. The NCI instance of caArray hosts many cancer-related public datasets available for download.

Cancer Schmancer’s mission is to shift the nations focus from just searching for a cure to prevention and early detection of cancer in order to save lives. The Cancer Schmancer Movement is a three-prong organization dedicated to early detection, prevention, and policy change

Children with Cancer UK is the leading national children's charity dedicated to the fight against all childhood cancers.

Around 2,400 children and teenagers are diagnosed with cancer every year in the UK. Our aims are to determine the causes, find cures and provide care for children with cancer.

The mission of The Childhood Leukemia Foundation (CLF) is to educate, empower and raise awareness and the necessary funds to support programs that benefit children living with cancer. Our programs improve health literacy, increase self-esteem and empower cancer victims with hope. CLF believes that by working together, we can make a difference one child at a time.

At CanTeen, we believe that no young person should have to face cancer alone.

CanTeen supports young people when cancer turns their world upside down and helps them cope with the physical, emotional and practical impact of living with cancer.

Established in 1983 in Atlanta, GA, the Brain Tumor Foundation for Children (BTFC) was the first nonprofit organization in the United States to focus on pediatric brain tumor disease.

The mission of the Brain Tumor Foundation for Children is to provide financial assistance, social support, and information for families of children with brain and spinal cord tumors; fund research projects that improve treatment options and search for a cure; and raise public awareness of the disease and advocate on behalf of children who are affected. 

ASK provides direct support to 1000 children with cancer and their families in Central Virginia on an annual basis. From the moment of diagnosis through treatment, ASK provides financial, spiritual, social and emotional support for children with cancer and their families. The unique positions and programs funded by ASK are an integral part of the ASK mission because they truly make a difference in the lives of children with cancer.

American Childhood Cancer Organization ( ACCO ) began in 1970 by a group of parents whose children had been diagnosed with cancer. They came together to lobby for more research, and to support each other through the diagnosis and treatment of this life threatening disease at a time when very few children survived. Today, ACCO is one of the largest grassroots, national organizations dedicated to improving the lives of children and adolescents with cancer and their families. We are strong advocates for our families in Washington D.C., we produce the highest quality materials on childhood cancer, and we have over 40 local affiliate organizations across the country providing direct services to the families in their communities.

When Alex, who was diagnosed with childhood cancer just before her first birthday, was four, she told her parents she wanted to set up a front-yard lemonade stand. Her plan: to give the money to doctors to help them find a cure. Her first “Alex’s Lemonade Stand”, held with the help of her older brother Patrick, raised an astonishing $2,000 in one day. While bravely fighting her own cancer, Alex continued to set up lemonade stands every year. As news spread of the remarkable girl so dedicated to helping other sick children, people everywhere were inspired to start their own lemonade stands—donating the proceeds to her cause.

In 2004 when Alex passed away at the age of eight—her stand and inspiration had raised more than $1 million towards finding a cure for the disease that took her life. Alex’s Lemonade Stand Foundation was started by her parents in 2005 to continue the work that Alex began. Our mission is simple: to raise money for and awareness of childhood cancer causes—especially research into new treatments and cures—and to encourage and empower others, especially children, to get involved and make a difference for children with cancer.

NBCF is a stabilizing force in the lives of hundreds of thousands of women who have reached a crossroad in their lives and need a helping hand to get across the bridge. NBCF offers free, innovative programs that other organizations aren’t providing to women facing breast cancer

At Relay For Life events, communities across the globe come together to honor cancer survivors, remember loved ones lost, and fight back against a disease that has already taken too much. The funds you raise truly make a difference in the fight against cancer – just ask one of the nearly 14 million cancer survivors who will celebrate another birthday this year!

Relay For Life teams camp out overnight and take turns walking or running around a track or path at a local high school, park, or fairground. Events are up to 24 hours long, and because cancer never sleeps, each team is asked to have at least one participant on the track at all times. 

As Australia's peak national non-government cancer control¹ organisation, Cancer Council Australia advises the Australian Government and other bodies on practices and policies to help prevent, detect and treat cancer. We also advocate for the rights of cancer patients for best treatment and supportive care.

Since 1982, Komen has played a critical role in every major advance in the fight against breast cancer – transforming how the world talks about and treats this disease and helping to turn millions of breast cancer patients into breast cancer survivors.

WACC (Women Against Cervical Cancer) is an initiative that aims to improve awareness of HPV and cervical diseases, and to make cervical cancer prevention a top priority on women's and public health agendas.

WACC was created - and will continue to be guided - by medical experts at the forefront of the field of cervical cancer, who will call on the skills of others with expertise in public health, education and project management to progress its work.

We believe that a nimble, focused and aggressive entrepreneurial model will increase the number of therapies discovered and then enable those therapies to be more rapidly driven into the clinic. We provide researchers with the pivotal support they need to make critical breakthroughs. We fund novel translational research aimed at finding the fastest possible route to a cure.

Our partners range from medical research centers to early-stage biotechnology companies to large multi-national pharmaceutical companies. These partners all share a vision of driving translational research and moving treatments as fast as possible from basic discovery to the clinic.

Since brain cancer affects a relatively small portion of the population, we recognize the importance of investing in the early stages of the most novel sectors of the discovery and development pipeline in order to “buy down the risk” for our partners and speed progress of innovative new treatments to the clinic.